Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



King's College London - Health: More than a medical matter





Gene therapy for muscle wasting conditions shows promise

15 November 2009

By Alison Cranage

Appeared in BioNews 534

Research published in the journal Science Translational Medicine last week shows gene therapy can improve muscle size and strength in monkeys. The technique holds promise as a therapy for several neuromuscular disorders, and researchers hope that clinical trials will start next year.

Researchers at Nationwide Children's Hospital, Columbus, US injected a virus containing a gene for follistatin protein directly into the thighs of monkeys. Follistatin protein inhibits the action of myostatin, a protein that inhibits muscle growth. The gene therapy resulted in long lasting increases in muscle size and strength in the monkeys, with no negative side effects.

Previously the gene therapy had been successfully tested in mice, and together with the new findings in monkeys, the team are hopeful that the technique could be used to improve muscle mass of people with neuromuscular disorders, such as muscular dystrophy.

'Our studies indicate that this relatively non-invasive approach could have long-term effects, involve few risks and could potentially be effective in various types of degenerative muscle disorders including multiple forms of muscular dystrophy', said the study's lead author, Dr Brian Kaspar.

The therapy would not be a cure for inherited conditions such as Duchenne muscular dystrophy (DMD), but it could limit the impact of disease and allow patients to retain the ability to walk for much longer.

'If we can improve the strength of muscles we can make a difference to the lives of these patients', said Professor Jerry Mendell, a specialist in muscle disease at Ohio State University and co-author of the study.

There may be other hurdles to overcome, as patients may need to take immunosuppressant drugs alongside the gene therapy. It will also have to be established that increasing muscle size is effective in treating diseases such as DMD, which affect muscle quality.

Marita Pohlschmidt, director of research at the Muscular Dystrophy Campaign, said: 'If proven to be safe and efficient, reducing the activity of myostatin could potentially be used to increase muscle strength for people with a broad range of neuromuscular conditions', adding 'these results, shown in healthy monkeys, are encouraging and represent another step forward in taking this therapeutic approach to clinical trial'.

 

SOURCES & REFERENCES
The Times | 12 November 2009
 
Reuters | 11 November 2009
 
Bloomberg | 11 November 2009
 
New Scientist blogs | 11 November 2009
 
The Scientist | 12 November 2009
 
Science Daily | 11 November 2009
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

07 October 2013 - by Robert Meadowcroft and Neil Bennett 
The families of children and young people with the severe genetic muscle-wasting condition Duchenne muscular dystrophy received a heavy blow last week... [Read More]
23 September 2013 - by Anna Cauldwell 
A highly anticipated experimental treatment for the genetic condition Duchenne Muscular Dystrophy has failed in a key test of its effectiveness in a critical phase III clinical trial.
13 June 2011 - by Sarah Guy 
The NHS must be prepared to screen every newborn baby for Duchenne muscular dystrophy (DMD) – the most severe form of muscular dystrophy – in three years time, says a leading UK geneticist who explains that promising treatments are close to becoming a reality... [Read More]
28 March 2011 - by Alison Cranage 
For the first time, gene therapy has shown promise for people with severe Parkinson's disease. Results from a proof of concept clinical trial in the US were published in the journal Lancet Neurology... [Read More]
07 March 2011 - by Dr Lux Fatimathas 
American researchers have successfully created immune cells resistant to HIV. T cells, which are the main target of HIV, were isolated from six HIV positive patients and genetically manipulated to confer resistance. The cells were injected back into the same patients and were able to survive and multiply... [Read More]

25 October 2009 - by Marianne Neary 
A potential new gene therapy for Duchenne Muscular Dystrophy (DMD) is now set to enter clinical trials after encouraging results in mice. The multinational team of scientists, publishing their findings in the journal Molecular Therapy, demonstrated that the therapy dramatically prevented severe muscle deterioration and extended the lifespan of mice with symptoms of DMD.... [Read More]
07 January 2008 - by Ailsa Stevens 
An experimental treatment for boys with the inherited muscle wasting disease Duchene Muscular Dystrophy (DMD) has showed promise in human safety trials, according to a study published in the New England Journal of Medicine. In the first ever trial on humans, the new drug was shown to... [Read More]
06 November 2007 - by Ailsa Stevens 
Last week the papers were flooded with reports of a so-called 'mighty mouse' - a genetically engineered mouse able to run for up to six hours at a speed of 20 metres per minute before needing a rest - created by researchers based at Case Western Reserve University in... [Read More]
24 September 2007 - by Ailsa Stevens 
The first trial of a new treatment for Duchenne muscular dystrophy (DMD) will start later this year in the UK. The treatment, which has been developed by using human cells and mice experiments, hopes to overcome the effects of the genetic defect that causes the muscle wasting... [Read More]
18 February 2004 - by BioNews 
Rats injected with a gene that promotes tissue growth develop stronger muscles after regular exercise, according to research presented at the annual meeting of the American Association for the Advancement of Science (AAAS) in Seattle. Scientists based at the University of Pennsylvania in Philadelphia, US, are hoping to develop new... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to Login or Register to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
RISK ASSESSMENT:
BREAST CANCER, PREDICTION AND SCREENING
FREE public event in central London, 6.30pm on Thursday 8 May 2014 - find out more HERE

ANNIVERSARY APPEAL
Please donate HERE, so that the Progress Educational Trust can continue throughout 2014 (and beyond) while keeping BioNews FREE for you to read

The Progress Educational Trust was shortlisted for the Charity Times Awards 2011

Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE, and give the Progress Educational Trust a regular donation